The domestic pharmaceutical industry argued that new domestic development drugs, which contributed to improving the financial soundness of health insurance through steady R&D investment, should be excluded from the list of "The Price-Volume Agreement (PVA)" or introduced a system that limits the number of applications. Even after the registration of new domestic drugs, additional clinical trials to enter overseas markets, and improve drug convenience have dampened the willingness to innovate management due to drug prices under the PVA system.

According to the pharmaceutical industry on the 9th, multiple pharmaceutical companies that succeeded in developing new drugs in Korea plan to point out the irrati